Lucid Diagnostics Q1 2024 Adj EPS $(0.21) Beats $(0.27) Estimate, Sales $1.001M Miss $1.046M Estimate
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics (NASDAQ:LUCD) reported Q1 2024 adjusted EPS of $(0.21), beating the $(0.27) estimate, but missed sales estimates with $1.001M against the expected $1.046M. The EPS represents a 12.5% improvement year-over-year, while sales saw a significant 124.44% increase from the previous year.
May 13, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lucid Diagnostics outperformed EPS estimates but slightly missed on sales forecasts for Q1 2024. The EPS improvement and significant sales growth year-over-year highlight the company's progress.
While beating EPS estimates is positive, missing sales forecasts could temper investor enthusiasm. The significant year-over-year sales growth indicates strong business growth, which could balance out the short-term impact of the sales miss. The mixed results may lead to neutral short-term price movement as investors weigh the EPS beat against the slight sales miss.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100